

**Douglas R. Martin, PhD**

*Selected Publications*

Rockwell HE, McCurdy VJ, Eaton SC, Wilson DU, Johnson AK, Bradbury AM, Gray-Edwards HL, Baker HJ, Hudson JA, Cox NR, Sena-Esteves M, Seyfried TN, **Martin DR**. AAV-mediated gene delivery corrects lysosomal storage in the feline central nervous system. *ASN Neuro*, 2014. (In preparation)

Larsen JM, **Martin DR**, Byrne ME. Effect of inulin and mannitol on the formation and maintenance of the diblock copolymer polyethylene glycol-b-poly(lactic acid). *Biomacromolecules*, 2014. (In preparation)

Bradbury AM, Peterson TA, Wells SZ, McCurdy VJ, Wolfe KG, Dennis JC, Brunson BL, Gray-Edwards HL, Randle AN, Morrison EE, Cox NR, Baker HJ, Sena-Esteves M, **Martin DR**. AAV-mediated gene delivery attenuates neuroinflammation associated with feline Sandhoff disease. *Human Molecular Genetics*, 2014. (In preparation)

Gray-Edwards HL, Brunson BL, Holland M, Hespel A-M, Bradbury AM, McCurdy VJ, Beadlescomb PM, Randle AN, Salibi N, Denney TS, Beyers RJ, Johnson AK, Montgomery RD, Wilson DU, Hudson JA, Cox NR, Baker HJ, Sena-Esteves M, **Martin DR**. Mucopolysaccharidosis-like phenotype in feline Sandhoff disease and partial correction after AAV gene therapy. *Journal of Inherited Metabolic Disease*, 2014. (Submitted for publication)

McCurdy VJ, Rockwell HE, Arthur JA, Bradbury AM, Johnson AK, Randle AN, Brunson BL, Hwang M, Gray-Edwards HL, Morrison NE, Johnson JA, Cox NR, Baker HJ, Seyfried TN, Sena-Esteves M, **Martin DR**. Widespread correction of central nervous system disease following intracranial gene therapy in a feline model of Sandhoff disease. *Gene Therapy*, 2014. (Accepted for publication)

Bradbury AM, Heather Gray-Edwards H, McCurdy VJ, Shirley JL, Colaco AN, Randle AN, Christopherson PW, Bird AC, De Pompa NL, Sorjonen DC, Brunson BL, Jeyakumar M, Platt FM, Cox NR, Baker HJ, Sena-Esteves M, **Martin DR**. Biomarkers for disease progression and AAV therapeutic efficacy in feline Sandhoff disease. *Experimental Neurology*, 2014. (Accepted for publication)

Samoylov AM, Napier ID, Morrison NE, **Martin DR**, Cox NR, Samoylova TI. Molecular cloning, sequencing, and distribution of feline gonadotropin releasing hormone receptor (GnRHR) and re-sequencing of canine GnRHR. *Theriogenology*, 2014. (Accepted for publication)

McCurdy VJ, Johnson AK, Gray-Edwards HL, Randle AN, Brunson BL, Morrison NE, Salibi N, Johnson JA, Hwang M, Beyers RJ, Leroy SG, Maitland S, Denney TS, Cox NR, Baker HJ, Sena-Esteves M, **Martin DR**. Sustained normalization of neurologic disease after intracranial gene therapy in a feline model. *Science Translational Medicine* 6:231ra48 (2014). doi: 10.1126/scitranslmed.3007733. PMID 24718858.

Larsen JM, **Martin DR**, Byrne ME. Recent advances in delivery through the blood-brain barrier. Current Topics in Medicinal Chemistry 14:1148-1160, 2014. PMID 24678707

Gray-Edwards HL, Salibi N, Josephson EM, Hudson JA, Cox NR, Randle AN, McCurdy VJ, Bradbury AM, Wilson DU, Beyers RJ, Denney TS, **Martin DR**. High resolution MRI anatomy of the cat brain at 3Tesla. Journal of Neuroscience Methods 227:10-17, 2014. PMID 24525327

Bradbury AM , Cochran JN, McCurdy VJ, Johnson AK, Brunson BL, Gray-Edwards H, Leroy SG, Hwang, Randle AN, Jackson LS, Morrison NE, Baek RC, Seyfried TN, Cheng SH, Cox NR, Baker HJ, Cachón-González MB, Cox TM, Sena-Esteves M, **Martin DR**. Therapeutic response in feline Sandhoff disease despite immunity to intracranial gene therapy. Molecular Therapy 21(7):1306-1315, 2013. PMID 23689599

Rigat BA, Tropak MB, Buttner J, Crushell E, Benedict D, Callahan JW, **Martin DR**, Mahuran DJ. Evaluation of N-nonyl-deoxygalactonojirimycin as a pharmacological chaperone for human GM1 gangliosidosis leads to identification of a feline model suitable for testing enzyme enhancement therapy. Molecular Genetics and Metabolism 107(1-2):203-212, 2012.

Baek RC, **Martin DR**, Cox NR, Seyfried TN. Comparative analysis of brain lipids in mice, cats, and humans with Sandhoff disease. Lipids 44:197-205, 2009.

Wang L, Shi J, van Ginkel FW, Lan L, Niemeyer G, **Martin DR**, Snyder EY, Cox NR. Neural stem/progenitor cells modulate immune responses by suppressing T lymphocytes with nitric oxide and prostaglandin E2. Experimental Neurology 216(1):177-183, 2009.

Bradbury AM, Morrison NE, Hwang M, Cox NR, Baker HJ, **Martin DR**. Neurodegenerative lysosomal storage disease in European Burmese cats with hexosaminidase beta-subunit deficiency. Mol Genet Metab 97:53-59, 2009.

Wang L, Shi J, van Ginkel FW, Lan L, Niemeyer G, **Martin DR**, Snyder EY, Cox NR. Neural stem/progenitor cells modulate immune responses by suppressing T lymphocytes with nitric oxide and prostaglandin E2. Exp Neurol 216(1):177-183, 2009.

Baek RC, **Martin DR**, Cox NR, Seyfried TN. Comparative analysis of brain lipids in mice, cats, and humans with Sandhoff disease. Lipids 44:197-205, 2008.

Vig K, Herzog R, **Martin D**, Moore EG, Dennis VA, Pillai S, Singh SR. Recombinant adeno-associated virus as vaccine delivery vehicles. Gene Ther Mol Biol 12:277-292, 2008.

**Martin DR**, Rigat BA, Foureman P, Varadarajan GS, Hwang M, Krum BK, Smith BF, Callahan JW, Mahuran DJ, Baker HJ. Molecular consequences of the pathogenic mutation in feline GM1 gangliosidosis. Molec Genet Metab 94:212-221, 2008.

Samoylova TI, **Martin DR**, Morrison NE, Hwang M, Cochran A, Samoylov A, Baker HJ, Cox NR. Generation and characterization of recombinant feline  $\beta$ -galactosidase for preclinical enzyme replacement therapy studies in GM1 gangliosidosis. Metab Brain Dis 23(2):161-73, 2008. Wang L, **Martin DR**, Baker HJ, Gentry AS, Zinn KR, Kappes JC Snyder EY, Cox NR.

Neural progenitor cell transplantation and imaging in a large animal model. *Neurosci Res* 59: 327-340, 2007.

**Martin DR**, Cox NR, Morrison NE, Kennamer DM, Peck SL, Dodson AN, Gentry AS, Griffin B, Rolsma MD, Baker HJ. Mutation of the GM2 activator protein in a feline model of GM2 gangliosidosis. *Acta Neuropathol* 110(5):443-50, 2005.

**Martin DR**, Krum BK, Varadarajan GS, Hathcock TL, Smith BF, Baker HJ. An inversion of 25 base pairs causes feline GM2 gangliosidosis variant 0. *Exp Neurol* 187:30-37, 2004.

**Martin DR**, Cox NR, Hathcock TL, Niemeyer GP, Baker HJ. Isolation and characterization of multipotential mesenchymal stem cells from feline bone marrow. *Exp Hematol* 30:879-886, 2002.

Book Chapters:

Golebiowski D, Bradbury AM, Kwon CS, van der Bom IMJ, Stoica L, Johnson AK, Wilson DU, Gray-Edwards HL, Hudson JA, Johnson JA, Randle AN, Whitlock BK, Sartin JL, Kühn AL, Gounis M, Asaad W, **Martin DR**, Sena-Esteves M. AAV gene therapy strategies for lysosomal storage disorders with central nervous system involvement. In *Neuromethods: Gene Delivery and Therapy for Neurological Disorders*, Bo X and Verhaagen J (eds.), 2014.

Seyfried TN, Rockwell HE, Heinicke KA, **Martin DR**, Sena-Esteves M. Ganglioside storage diseases: on the road to management. In *Advances in Neurobiology: Glycobiology of the Nervous System*, Shengrund (ed.), 9:485-499, 2014.

Baker HJ, Smith BF, **Martin DR**, Foureman P. Molecular diagnosis of gangliosidoses: a model for elimination of inherited diseases in pure breeds. In *Consultations in Feline Internal Medicine*, 4th ed, August JR (ed.), W.B. Saunders (Orlando) 615-620, 2001.